Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11357779 G1T38 superior dosage regimes

Patent 11357779 was granted and assigned to G1 Therapeutics on June, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
G1 Therapeutics
G1 Therapeutics
Date Filed
July 8, 2020
Date of Patent
June 14, 2022
Patent Applicant
G1 Therapeutics
G1 Therapeutics
Patent Application Number
16924033
Patent Citations
‌
US Patent 10189851 CDK inhibitors
‌
US Patent 10076523 HSPC-sparing treatments for RB-positive abnormal cellular proliferation
‌
US Patent 10085992 Transient protection of normal cells during chemotherapy
‌
US Patent 10189849 CDK inhibitors
‌
US Patent 10189850 CDK inhibitors
‌
US Patent 10231969 Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumors
Patent Citations Received
‌
US Patent 11643416 Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11357779
Patent Primary Examiner
‌
Erich A Leeser
CPC Code
‌
A61K 31/519
‌
A61K 31/506

Find more entities like US Patent 11357779 G1T38 superior dosage regimes

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.